RT Journal Article
SR Electronic
T1 Severity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.23.21265402
DO 10.1101/2021.10.23.21265402
A1 Priya R. Edward
A1 Ramon Lorenzo-Redondo
A1 Megan E. Reyna
A1 Lacy M. Simons
A1 Judd F. Hultquist
A1 Ami B. Patel
A1 Egon A. Ozer
A1 William J. Muller
A1 Taylor Heald-Sargent
A1 Matthew McHugh
A1 Taylor J. Dean
A1 Raj M. Dalal
A1 Jordan John
A1 Shannon C. Manz
A1 Larry K. Kociolek
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.23.21265402.abstract
AB Background Recent surges in coronavirus 2019 disease (COVID-19) is attributed to the emergence of more transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs). However, the relative severity of SARS-CoV-2 VOCs in children is unknown.Methods This retrospective single-center cohort study was performed at the Ann & Robert H. Lurie Children’s Hospital of Chicago, academic free-standing children’s hospital. We included all children ≤ 18 years-old diagnosed with COVID-19 between October 15th, 2020 and August 31st, 2021 and whose SARS-CoV-2 isolate was sequenced using the Illumina platform. For each patient sample, we identified the SARS-CoV-2 lineage, which was assigned to one of the following groups: Non-VOC, alpha VOC, beta VOC, gamma VOC, or delta VOC. We measured frequency of 5 markers of COVID-19 severity: hospitalization; COVID-19 pharmacologic treatment; respiratory support; intensive care unit admission; and severe disease as classified by the COVID-19 World Health Organization (WHO) Clinical Progression Scale (severe disease; score ≥ 6). A series of logistic regression models were fitted to estimate odds of each severity marker with each VOC (in comparison to non-VOCs), adjusting for COVID-19 community incidence and demographic and clinical co-variates.Results During the study period, 2,025 patients tested positive for SARS-CoV-2; 1,422 (70.2%) had sufficient viral load to permit sequencing. Among the 499 (35.1%) patients whose isolate was sequenced, median (inter-quartile range) age was 7 (1,12) years; 256 (51.3%) isolates were a VOC: 96 (37.5%) alpha, 38 (14.8%) gamma, and 119 (46.5%) delta. After adjusting for age, Black race, Hispanic ethnicity, high-risk medical conditions, and COVID-19 community incidence, neither alpha nor delta was associated with severe COVID-19. Gamma was independently associated with hospitalization (OR 5.9, 95% CI 1.6-21.5, p=0.007), respiratory support (OR 8.3, 95% CI 1.5-56.3, p=0.02), and severe disease as classified by the WHO Clinical Progression Scale (OR 7.7, 95% CI 1.0-78.1, p=0.05).Conclusions Compared to non-VOC COVID-19 infections, the gamma VOC, but not the alpha or delta VOCs, was associated with increased severity. These data suggest that recent increased in pediatric COVID-19 hospitalizations are related to increased delta COVID-19 incidence rather than increased delta virulence in children.Competing Interest StatementL.K.K. reports having received research funding from Merck, unrelated to this study. J.F.H. reports having received research funding from Gilead, unrelated to this study. All other authors report no conflicts of interest.Funding StatementThis work was partially supported by funding to L.K.K., J.F.H., E.A.O., L.M.S., and R.L.R. from the Walder Foundation Chicago Coronavirus Assessment Network (Chicago CAN) Initiative. Research reported in this publication was also supported, in part, by: the National Institutes of Health's (NIH) National Center for Advancing Translational Sciences (NCATS) UL1 TR001422 (L.K.K., J.F.H., E.A.O., L.M.S., and R.L.R.); a Dixon Translational Research Grant made possible by the generous support of the Dixon Family Foundation (E.A.O. and J.F.H.); an NIH CTSA supplement to UL1 TR002389 (J.F.H., E.A.O., R.L.R.); a supplement to the Northwestern University Cancer Center P30 CA060553 (J.F.H.); and NIH grant U19 AI135964 (E.A.O.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Lurie Childrens Institutional Review Board approved this study (IRB 2020-3792).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript